Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Central memory T cells (Tcm) are a subtype of T lymphocytes with high expression of CCR7 and CD62L, which allows them to home to secondary lymphoid tissues and persist long-term. When engineered or expanded to be tumor antigen-specific, these cells can mount a robust immune response against tumor cells upon adoptive transfer into patients. Compared to effector or effector memory T cells, Tcm display superior proliferation, persistence, and recall responses, making them attractive for adoptive cell therapy of cancer. These Tcm recognize tumor antigens via their TCR, become activated, proliferate, and kill target cells through the release of cytolytic granules and cytokines.
Cell-mediated cytotoxicity via T cell receptor (TCR) recognition of tumor antigen-MHC complexes; Release of perforin/granzymes leading to tumor cell lysis; Production of cytokines (e.g., IFN-γ, TNF-α); Expansion and persistence upon antigen re-exposure
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Central memory cytotoxic T cell (Tcm cytotoxic T cell (CD8+ Tcm)).